0.23%

Gold vs US Dollar

Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Get Started

GSK Gsk Plc

1,705.00

32.00 (1.91%)

01 May 2024 - Closed

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Gsk Plc	LSE:GSK	London	Ordinary Share	GB00BN7SWP63	ORD 31 1/4P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	32.00	1.91%	1,705.00	1,701.00	1,701.50	1,718.50	1,673.00	1,685.50	5,853,296	16:35:27

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
Pharmaceutical Preparations	30.33B	4.93B	1.1970	14.21	70.03B

GlaxoSmithKline: Phase 3 Study of Zejula Met Trial Objectives

15/07/2019 7:43am

Dow Jones News

Gsk (LSE:GSK)
Historical Stock Chart

From May 2019 to May 2024

   By Carlo Martuscelli

GlaxoSmithKline PLC (GSK.LN) said Monday that a phase 3 study of its cancer drug niraparib, which is marketed under the name Zejula, yielded positive results.

The drug demonstrated a statistically-meaningful improvement in survival without disease progression in women with ovarian cancer, regardless of their biomarker status, the British pharmaceutical company said.

Safety results were consistent with previous clinical trials. The medication was being administered as a first-line maintenance treatment following platinum based chemotherapy.

GlaxoSmithKline said full results from the study, called Prima, will be made public at an upcoming scientific meeting.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

(END) Dow Jones Newswires

July 15, 2019 02:28 ET (06:28 GMT)